Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Chronic β2AR stimulation limits CFTR activation in human airway epithelia
John J. Brewington, … , L. Jason Lu, John P. Clancy
John J. Brewington, … , L. Jason Lu, John P. Clancy
Published February 22, 2018
Citation Information: JCI Insight. 2018;3(4):e93029. https://doi.org/10.1172/jci.insight.93029.
View: Text | PDF
Research Article Cell biology Pulmonology

Chronic β2AR stimulation limits CFTR activation in human airway epithelia

  • Text
  • PDF
Abstract

Traditional pulmonary therapies for cystic fibrosis (CF) target the downstream effects of CF transmembrane conductance regulator (CFTR) dysfunction (the cause of CF). Use of one such therapy, β-adrenergic bronchodilators (such as albuterol), is nearly universal for airway clearance. Conversely, novel modulator therapies restore function to select mutant CFTR proteins, offering a disease-modifying treatment. Recent trials of modulators targeting F508del-CFTR, the most common CFTR mutation, suggest that chronic β-agonist use may undermine clinical modulator benefits. We therefore sought to understand the impact of chronic or excess β-agonist exposure on CFTR activation in human airway epithelium. The present studies demonstrate a greater than 60% reduction in both wild-type and modulator-corrected F508del-CFTR activation following chronic exposure to short- and long-acting β-agonists. This reduction was due to reduced cellular generation of cAMP downstream of the β-2 adrenergic receptor–G protein complex. Our results point towards a posttranscriptional reduction in adenylyl cyclase function as the mechanism of impaired CFTR activation produced by prolonged β-agonist exposure. β-Agonist–induced CFTR dysfunction was sufficient to abrogate VX809/VX770 modulation of F508del-CFTR in vitro. Understanding the clinical relevance of our observations is critical for CF patients using these drugs, and for investigators to inform future CFTR modulator drug trials.

Authors

John J. Brewington, Jessica Backstrom, Amanda Feldman, Elizabeth L. Kramer, Jessica D. Moncivaiz, Alicia J. Ostmann, Xiaoting Zhu, L. Jason Lu, John P. Clancy

×

Figure 5

Chronic albuterol exposure does not reduce CFTR expression or maturation in wtCFTR+ or F508del-CFTR+ CFBE41o- cells.

Options: View larger image (or click on image) Download as PowerPoint
Chronic albuterol exposure does not reduce CFTR expression or maturation...
wtCFTR+ and VX809-corrected F508del-CFTR+ CFBE41o- cells were continuously exposed to albuterol (10 μM), lysed, and CFTR protein was isolated by Western blot. Both C- and B-band forms were quantified by densitometry (relative to β-actin). Representative CFTR Western blots of wtCFTR+ (A) and VX809-corrected F508del-CFTR+ (B) CFBE41o- cells following selective 72-hour pretreatment with albuterol. Each lane represents a separate insert; within each donor, all lanes were run in the same gel, but were noncontiguous. Densitometry corrected to β-actin shows no difference in mature C-band CFTR levels in either wtCFTR+ (C) or F508del-CFTR+ (D) CFBE41o- cells (n = 3 inserts/lanes). These experiments are representative of studies repeated in duplicate with similar results. Data presented represent the mean ± SEM. NS, nonsignificant by 2-tailed t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts